Halozyme Therapeutics | HALO - Sales Revenues


Halozyme Therapeutics reported $451.76M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Acadia Pharmaceuticals USD 284M 5.4M Dec/2025
Agios Pharmaceuticals USD 19.97M 7.07M Dec/2025
Alnylam Pharmaceuticals USD 1.1B 150M Dec/2025
Amarin USD 49.67M 23.07M Sep/2025
Amgen USD 9.9B 340M Dec/2025
Baxter International USD 2.97B 130M Dec/2025
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Cytokinetics USD 17.76M 15.83M Dec/2025
DBV Technologies USD 2.77M 1.31M Sep/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Esperion Therapeutics USD 168.45M 81.14M Dec/2025
Halozyme Therapeutics USD 451.76M 97.76M Dec/2025
Intrexon USD 717K 511K Jun/2024
Ionis Pharmaceuticals USD 203M 46M Dec/2025
MannKind USD 111.96M 29.83M Dec/2025
Minerva Neurosciences USD 0 0 Sep/2024
Nektar Therapeutics USD 24.12M 635K Sep/2024
Pfizer USD 17.58B 880M Dec/2025
Rigel Pharmaceuticals USD 55.31M 18.47M Sep/2024
United Therapeutics USD 790.2M 9.3M Dec/2025
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024